ClinicalTrials.gg
CompletedNCT02285504Updated Sep 15, 2025Results posted

Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

A Phase 2 interventional study of SAGE-547 in Postpartum Depression, sponsored by Supernus Pharmaceuticals, Inc.. Completed at 1 site in United States. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Supernus Pharmaceuticals, Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
4
Allocation
Not applicable
Ages
18 Years to 45 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 220 studies in Depression, Postpartum with a site in United States — 38 open to participants now, 49 under way, 3 of them phase 3. Depression, Postpartum · United States.

Enrollment
189th of 198
4 · median 86
Started
2015
with 7 others
Phase 2
18 of 220
none open now
Registered
63rd of 220
by date
Lead sponsor
6 of 220
Supernus Pharmaceuticals, Inc.

Among the 220 studies in Depression, Postpartum with a site in United States, this one is the 189th largest by enrollment of the 198 interventional ones that give a count, is one of 8 that started in 2015, is one of 18 in phase 2, and was the 63rd registered.

Depression, Postpartum

569 studies on the registry are indexed under Depression, Postpartum; 134 are open to participants now.

Browse Depression, Postpartum studies →

Open to participants now

38 of the 220 studies in Depression, Postpartum with a site in United States are open now. Recruiting first, the newest first:

33 more — sign in →

All 38 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 87 Depression, Postpartum studies recruiting now, 54 (62%) set no upper age limit and 30 (34%) stop at 75 or younger; 13 take children under 18; 40 take healthy volunteers.

This study: 18 Years to 45 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 220 studies in Depression, Postpartum with a site in United States, or all of them as a file.
02

Study summary

This is an open-label proof-of-concept study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of SAGE-547 Injection in adult female participants diagnosed with severe postpartum depression (PPD).

03

Conditions studied

  • Postpartum Depression

Keywords

  • Postpartum depression
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult females, 18-45 years old who experienced a major depressive episode in the postpartum period beginning within the first 4 weeks following delivery
  • Participant has ceased lactating, or if still lactating has already fully and permanently weaned their infant; if still actively breastfeeding, participant must agree to cease giving breast milk to their infant prior to study entry

Exclusion criteria

Exclusion Criteria:

  • Recent history or active manifestations of metabolic, hepatic, renal, hematological, pulmonary, cardiovascular, gastrointestinal, musculoskeletal, dermatological, urogenital, or eyes, ears, or nose and throat (EENT) disorders
  • Active psychosis
  • Medical history of seizures
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    SAGE-547

    Participants received SAGE-547 intravenous injection over 60 hours (including 12-hour titration infusion of 21.5 micrograms per kilogram per hour \[mcg/kg/hr\] \[4 hrs\], 43 mcg/kg/hr \[4 hrs\] and 64.5 mcg/kg/hr \[4 hrs\] on Day 1, followed by 13 to 48 hrs \[36 hrs\] maintenance infusion of 86 mcg/kg/hr from Day 1 to 3, followed by a 12-hr taper infusion of 64.5 mcg/kg/hr \[49 - 52 hrs\], 43 mcg/kg/hr \[53 - 56 hrs\] and 21.5 mcg/kg/hr \[57 - 60 hrs\] on Day 3).

    Drug: SAGE-547

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

    AEs were any untoward medical occurrences in a participant who received study treatment without regard to possibility of causal relationship. TEAEs were defined as AEs with onset after the start of SAGE-547 infusion, or any worsening of a pre-existing medical condition or AEs with onset after the start of SAGE-547 infusion and until 7 days after the end of infusion (Day 11). TESAEs were defined as AEs with onset after the start of SAGE-547 infusion, or any worsening of a pre-existing medical condition or AEs with onset after the start of SAGE-547 infusion and until 30 days after the end of infusion (Day 34).

    Time frame: TEAEs: Up to Day 11, TESAEs: Up to Day 34

  2. Change From Baseline in Clinical Laboratory Measures: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT)

    Clinical laboratory evaluation included: Chemistry (ALT, AST, GGT) expressed in terms of units per liter (U/L). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  3. Change From Baseline in Clinical Laboratory Measures: Carbon Dioxide (CO2), Sodium, Potassium and Chloride

    Clinical laboratory evaluation included: Chemistry (carbon dioxide \[CO2\], sodium, potassium and chloride) expressed in terms of millimoles/liter (mmol/L). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  4. Change From Baseline in Clinical Laboratory Measures: Glucose, Total Bilirubin, Calcium, Blood Urea Nitrogen (BUN) and Creatinine

    Clinical laboratory evaluation included: Chemistry (glucose, total bilirubin, calcium, blood urea nitrogen \[BUN\] and creatinine) expressed in terms of milligrams/deciliter (mg/dL). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  5. Change From Baseline in Clinical Laboratory Measures: Albumin, Total Protein and Hemoglobin

    Clinical laboratory evaluation included: Chemistry (albumin, total protein), Hematology and Coagulation (hemoglobin) expressed in terms of g/dL. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  6. Change From Baseline in Clinical Laboratory Measure: Hematocrit

    Clinical laboratory evaluation included: Hematocrit expressed in terms of percentage. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  7. Change From Baseline in Clinical Laboratory Measures: Platelet Count, White Blood Cells (WBC), Absolute Lymphocytes, Absolute Neutrophils, Absolute Basophils, Absolute Eosinophils, Absolute Monocytes

    Clinical laboratory evaluation included: Platelet count, white blood cells (WBC), absolute lymphocytes, absolute neutrophils, absolute basophils, absolute eosinophils, absolute monocytes expressed in terms of 10\^9 cells/L. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  8. Change From Baseline in Clinical Laboratory Measure: Red Blood Cells (RBC)

    Clinical laboratory evaluation included: RBC expressed in terms of 10\^12 cells/L. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  9. Change From Baseline in Clinical Laboratory Measure: Mean Corpuscular Volume (MCV)

    Clinical laboratory evaluation included: MCV expressed in terms of femtoliters (fL). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  10. Change From Baseline in Clinical Laboratory Measure: Mean Corpuscular Hemoglobin (MCH)

    Clinical laboratory evaluation included: MCH expressed in terms of picogram (pg). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  11. Change From Baseline in Clinical Laboratory Measure: Prothrombin Time/International Normalized Ratio (PT/INR)

    Clinical laboratory evaluation included: PT/INR expressed in terms of seconds. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  12. Change From Baseline in Clinical Laboratory Measure: Potential of Hydrogen (pH)

    Clinical laboratory evaluation included: Urinalysis (pH). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  13. Change From Baseline in Clinical Laboratory Measure: Specific Gravity

    Clinical laboratory evaluation included: Urinalysis (specific gravity) expressed in terms of ratio. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

    Time frame: Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)

  14. Change From Baseline in Vital Sign: Blood Pressure

    Vital sign parameters included supine systolic blood pressure (SBP), supine diastolic blood pressure (DBP), standing systolic blood pressure and standing diastolic blood pressure expressed in terms of millimeters of mercury (mmHg). The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).

    Time frame: Baseline, Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)

  15. Change From Baseline in Vital Sign: Heart Rate

    Vital sign parameter included heart rate expressed in terms of beats per minute (bpm). The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).

    Time frame: Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)

  16. Change From Baseline in Vital Sign: Body Temperature

    Vital sign parameter included temperature expressed in terms of degree Celsius. The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).

    Time frame: Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)

  17. Change From Baseline in Vital Sign: Respiratory Rate

    Vital sign parameter included respiratory rate expressed in terms of breaths per minute. The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).

    Time frame: Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)

  18. Change From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, PR Interval, QTc Interval, and QRS Duration

    ECGs parameters included QT interval, PR interval, QTc interval, QRS duration expressed in terms of milliseconds (msec).

    Time frame: Baseline, Day 4 (at 84 hrs)

  19. Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate

    ECGs parameter included heart rate expressed in terms of beats per minute (bpm).

    Time frame: Baseline, Day 4 (at 84 hrs)

  20. Number of Participants With Physical Examination Findings

    Physical examinations included body weight, height, body mass index (BMI) and assessment of body systems (e.g., head, eyes, ears, nose, throat, lungs, abdomen, and extremities) as well as cognitive and mental health examinations (components of the neurological and psychiatric examinations, respectively).

    Time frame: At Day 4

  21. Number of Participants With Concomitant Medication Usage

    Concomitant medications are other prescription medications, over the counter (OTC) drugs or dietary supplements that a study participant takes in addition to the drug under investigation.

    Time frame: Baseline up to Day 11

  22. Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

    C-SSRS scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicidal ideation and behavior, and a post-baseline evaluation that focuses on suicidality since the last study visit. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, (with score range from 1 to 5, higher score indicates more severity). The data was collected at time-points: Pre-infusion (Day 1 prior to dosing), Post-infusion (any time after the start of infusion on Day 1 up to 84 hrs).

    Time frame: Pre-infusion (Day 1 prior to dosing), Post-infusion (any time after the start of infusion on Day 1 up to 84 hrs)

Secondary outcomes

  1. Maximum Plasma Concentration (Cmax) of SAGE-547

    Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose

  2. Time to Maximum Plasma Concentration (Tmax) of SAGE-547

    Tmax is defined as the time at which Cmax of SAGE-547 occurred.

    Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose

  3. Area Under the Concentration-Time Curve From Start of the Infusion Until the Time of the Last Sample (AUCall) of SAGE-547

    AUCall is defined as the area under the plasma SAGE-547 concentration time curves from the start of the infusion until the time the last sample was taken 72 hours later.

    Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose

  4. Area Under the Concentration-Time Curve From Time Zero to 60 Hours (AUC0-60) of SAGE-547

    AUC0-60 is defined as the area under the plasma SAGE-547 concentration time curve during the intravenous infusion.

    Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, and 60 hrs post-dose

  5. Area Under the Concentration-Time Curve in 24 Hours (AUC24) of SAGE-547

    AUC24 is defined as the area under the plasma SAGE-547 concentration-time curve in a 24-hour period during the maintenance dose.

    Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, and 24 hrs post-dose

  6. Average Drug Concentration in the Plasma at Steady State During a Dosing Interval (Cavg) of SAGE-547

    Cavg is defined as the plasma concentration of SAGE-547 at steady-state (average plasma concentration during the maintenance dose period; nominally 12 to 48 hrs).

    Time frame: From 12 to 48 hrs (36 hr of maintenance dose period)

  7. Plasma Clearance (CL) of SAGE-547

    Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes.

    Time frame: Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose

  8. Change From Baseline in Hamilton Rating Scale for Depression-17 (HAM-D-17) Total Score

    The HAM-D-17 was used to rate the severity of depression in participants who were already diagnosed as depressed. The HAM-D-17 is comprised of 17 individual items: Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis, where 0 indicated none/absent and higher scores indicated greater depression. The Total Score can range from 0 (least depression) to 52 (greater depression), and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

    Time frame: Baseline, Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), Day 3 (at 48 and 60 hrs), and Day 4 (at 84 hrs)

  9. Clinical Global Impression-Improvement (CGI-I) Score

    The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I assessment employs a 7-point Likert scale to measure the improvement in the participant's condition. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.

    Time frame: Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 84 hrs)

07

Results

Posted Dec 2, 2021

Participant flow

Participants were enrolled in the study at 1 center in the United States from 07 January 2015 to 05 June 2015.

Participant flow — Overall Study
MilestoneSAGE-547
Started4
Completed4
Not completed0

Outcome measures

PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)

AEs were any untoward medical occurrences in a participant who received study treatment without regard to possibility of causal relationship. TEAEs were defined as AEs with onset after the start of SAGE-547 infusion, or any worsening of a pre-existing medical condition or AEs with onset after the start of SAGE-547 infusion and until 7 days after the end of infusion (Day 11). TESAEs were defined as AEs with onset after the start of SAGE-547 infusion, or any worsening of a pre-existing medical condition or AEs with onset after the start of SAGE-547 infusion and until 30 days after the end of infusion (Day 34).

Time frame:
TEAEs: Up to Day 11, TESAEs: Up to Day 34
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs)
ParticipantsSAGE-547
TEAEs4
TESAEs0
PrimaryChange From Baseline in Clinical Laboratory Measures: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT)

Clinical laboratory evaluation included: Chemistry (ALT, AST, GGT) expressed in terms of units per liter (U/L). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · U/L
Change From Baseline in Clinical Laboratory Measures: Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Gamma Glutamyl Transferase (GGT)
U/LSAGE-547
Change From Baseline at Day 2 (24 hrs): ALT-3.0 ± 4.69
Change From Baseline at Day 3 (48 hrs): ALT-3.7 ± 7.02
Change From Baseline at Day 4 (84 hrs): ALT2.7 ± 2.08
Change From Baseline at Day 2 (24 hrs): AST-0.5 ± 6.19
Change From Baseline at Day 3 (48 hrs): AST1.0 ± 6.24
Change From Baseline at Day 4 (84 hrs): AST4.7 ± 5.69
Change From Baseline at Day 2 (24 hrs): GGT-0.7 ± 2.08
Change From Baseline at Day 3 (48 hrs): GGT-2.0 ± 1.41
Change From Baseline at Day 4 (84 hrs): GGT5.5 ± 9.19
PrimaryChange From Baseline in Clinical Laboratory Measures: Carbon Dioxide (CO2), Sodium, Potassium and Chloride

Clinical laboratory evaluation included: Chemistry (carbon dioxide \[CO2\], sodium, potassium and chloride) expressed in terms of millimoles/liter (mmol/L). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · mmol/L
Change From Baseline in Clinical Laboratory Measures: Carbon Dioxide (CO2), Sodium, Potassium and Chloride
mmol/LSAGE-547
Change From Baseline at Day 2 (24 hrs): CO2-0.5 ± 3.42
Change From Baseline at Day 3 (48 hrs): CO2-2.0 ± 3.61
Change From Baseline at Day 4 (84 hrs): CO2-3.0 ± 4.58
Change From Baseline at Day 2 (24 hrs): Sodium-0.5 ± 1.00
Change From Baseline at Day 3 (48 hrs): Sodium-1.3 ± 2.08
Change From Baseline at Day 4 (84 hrs): Sodium1.3 ± 2.52
Change From Baseline at Day 2 (24 hrs): Potassium0.25 ± 0.208
Change From Baseline at Day 3 (48 hrs): Potassium0.20 ± 0.100
Change From Baseline at Day 4 (84 hrs): Potassium0.47 ± 0.115
Change From Baseline at Day 2 (24 hrs): Chloride-0.5 ± 5.00
Change From Baseline at Day 3 (48 hrs): Chloride-1.3 ± 5.03
Change From Baseline at Day 4 (84 hrs): Chloride-1.3 ± 6.03
PrimaryChange From Baseline in Clinical Laboratory Measures: Glucose, Total Bilirubin, Calcium, Blood Urea Nitrogen (BUN) and Creatinine

Clinical laboratory evaluation included: Chemistry (glucose, total bilirubin, calcium, blood urea nitrogen \[BUN\] and creatinine) expressed in terms of milligrams/deciliter (mg/dL). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · mg/dL
Change From Baseline in Clinical Laboratory Measures: Glucose, Total Bilirubin, Calcium, Blood Urea Nitrogen (BUN) and Creatinine
mg/dLSAGE-547
Change at Day 2 (24 hrs): Glucose16.0 ± 15.90
Change at Day 3 (48 hrs): Glucose28.3 ± 31.37
Change at Day 4 (84 hrs): Glucose17.7 ± 13.58
Change at Day 2 (24 hrs): Total Bilirubin-0.05 ± 0.129
Change at Day 3 (48 hrs): Total Bilirubin-0.23 ± 0.153
Change at Day 4 (84 hrs): Total Bilirubin-0.13 ± 0.115
Change at Day 2 (24 hrs): Calcium-0.28 ± 0.532
Change at Day 3 (48 hrs): Calcium-0.03 ± 0.802
Change at Day 4 (84 hrs): Calcium0.30 ± 0.265
Change at Day 2 (24 hrs): BUN0.5 ± 1.29
Change at Day 3 (48 hrs): BUN0.3 ± 4.51
Change at Day 4 (84 hrs): BUN0.0 ± 4.58
Change at Day 2 (24 hrs): Creatinine-0.010 ± 0.0698
Change at Day 3 (48 hrs): Creatinine-0.050 ± 0.0721
Change at Day 4 (84 hrs): Creatinine-0.057 ± 0.1159
PrimaryChange From Baseline in Clinical Laboratory Measures: Albumin, Total Protein and Hemoglobin

Clinical laboratory evaluation included: Chemistry (albumin, total protein), Hematology and Coagulation (hemoglobin) expressed in terms of g/dL. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · g/dL
Change From Baseline in Clinical Laboratory Measures: Albumin, Total Protein and Hemoglobin
g/dLSAGE-547
Change at Day 2 (24 hrs): Albumin-0.40 ± 0.497
Change at Day 3 (48 hrs): Albumin-0.33 ± 0.551
Change at Day 4 (84 hrs): Albumin0.20 ± 0.173
Change at Day 2 (24 hrs): Total Protein-0.63 ± 0.499
Change at Day 3 (48 hrs): Total Protein-0.43 ± 0.702
Change at Day 4 (84 hrs): Total Protein0.20 ± 0.361
Change at Day 2 (24 hrs): Hemoglobin0.02 ± 0.943
Change at Day 3 (48 hrs): Hemoglobin-0.10 ± 0.954
Change at Day 4 (84 hrs): Hemoglobin0.27 ± 0.306
PrimaryChange From Baseline in Clinical Laboratory Measure: Hematocrit

Clinical laboratory evaluation included: Hematocrit expressed in terms of percentage. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · percentage of hematocrit
Change From Baseline in Clinical Laboratory Measure: Hematocrit
percentage of hematocritSAGE-547
Change From Baseline at Day 2 (24 hrs)0.15 ± 2.199
Change From Baseline at Day 3 (48 hrs)-1.07 ± 1.914
Change From Baseline at Day 4 (84 hrs)1.20 ± 1.311
PrimaryChange From Baseline in Clinical Laboratory Measures: Platelet Count, White Blood Cells (WBC), Absolute Lymphocytes, Absolute Neutrophils, Absolute Basophils, Absolute Eosinophils, Absolute Monocytes

Clinical laboratory evaluation included: Platelet count, white blood cells (WBC), absolute lymphocytes, absolute neutrophils, absolute basophils, absolute eosinophils, absolute monocytes expressed in terms of 10\^9 cells/L. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Clinical Laboratory Measures: Platelet Count, White Blood Cells (WBC), Absolute Lymphocytes, Absolute Neutrophils, Absolute Basophils, Absolute Eosinophils, Absolute Monocytes
10^9 cells/LSAGE-547
Change at Day 2 (24 hrs): Platelet Count-18.8 ± 16.50
Change at Day 3 (48 hrs): Platelet Count-23.3 ± 27.65
Change at Day 4 (84 hrs): Platelet Count-4.3 ± 37.98
Change at Day 2 (24 hrs): WBC-0.93 ± 1.910
Change at Day 3 (48 hrs): WBC-0.03 ± 3.287
Change at Day 4 (84 hrs): WBC-1.07 ± 1.069
Change at Day 2 (24 hrs): Absolute Lymphocytes-0.73 ± 0.764
Change at Day 3 (48 hrs): Absolute Lymphocytes-0.50 ± 1.273
Change at Day 4 (84 hrs): Absolute Lymphocytes-0.57 ± 0.737
Change at Day 2 (24 hrs): Absolute Neutrophils-0.933 ± 0.2082
Change at Day 3 (48 hrs): Absolute Neutrophils-1.250 ± 0.2121
Change at Day 4 (84 hrs): Absolute Neutrophils-0.467 ± 0.2082
Change at Day 2 (24 hrs): Absolute Basophils0.0 ± 0.00
Change at Day 3 (48 hrs): Absolute Basophils0.0 ± 0.00
Change at Day 4 (84 hrs): Absolute Basophils0.0 ± 0.00
Change at Day 2 (24 hrs): Absolute Eosinophils0.03 ± 0.058
Change at Day 3 (48 hrs): Absolute Eosinophils0.05 ± 0.071
Change at Day 4 (84 hrs): Absolute Eosinophils0.00 ± 0.100
Change at Day 2 (24 hrs): Absolute Monocytes-0.10 ± 0.100
Change at Day 3 (48 hrs): Absolute Monocytes-0.05 ± 0.071
Change at Day 4 (84 hrs): Absolute Monocytes-0.07 ± 0.058
PrimaryChange From Baseline in Clinical Laboratory Measure: Red Blood Cells (RBC)

Clinical laboratory evaluation included: RBC expressed in terms of 10\^12 cells/L. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · 10^12 cells/L
Change From Baseline in Clinical Laboratory Measure: Red Blood Cells (RBC)
10^12 cells/LSAGE-547
Change From Baseline at Day 2 (24 hrs)-0.030 ± 0.1924
Change From Baseline at Day 3 (48 hrs)-0.090 ± 0.2784
Change From Baseline at Day 4 (84 hrs)0.113 ± 0.1656
PrimaryChange From Baseline in Clinical Laboratory Measure: Mean Corpuscular Volume (MCV)

Clinical laboratory evaluation included: MCV expressed in terms of femtoliters (fL). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · fL
Change From Baseline in Clinical Laboratory Measure: Mean Corpuscular Volume (MCV)
fLSAGE-547
Change From Baseline at Day 2 (24 hrs)0.85 ± 1.578
Change From Baseline at Day 3 (48 hrs)-0.53 ± 0.924
Change From Baseline at Day 4 (84 hrs)0.33 ± 1.155
PrimaryChange From Baseline in Clinical Laboratory Measure: Mean Corpuscular Hemoglobin (MCH)

Clinical laboratory evaluation included: MCH expressed in terms of picogram (pg). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · pg
Change From Baseline in Clinical Laboratory Measure: Mean Corpuscular Hemoglobin (MCH)
pgSAGE-547
Change From Baseline at Day 2 (24 hrs)-0.3 ± 1.15
Change From Baseline at Day 3 (48 hrs)0.5 ± 0.71
Change From Baseline at Day 4 (84 hrs)-0.3 ± 1.15
PrimaryChange From Baseline in Clinical Laboratory Measure: Prothrombin Time/International Normalized Ratio (PT/INR)

Clinical laboratory evaluation included: PT/INR expressed in terms of seconds. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · seconds
Change From Baseline in Clinical Laboratory Measure: Prothrombin Time/International Normalized Ratio (PT/INR)
secondsSAGE-547
Change From Baseline at Day 2 (24 hrs)-0.30 ± 0.700
Change From Baseline at Day 3 (48 hrs)-1.05 ± 0.636
Change From Baseline at Day 4 (84 hrs)-0.37 ± 0.902
PrimaryChange From Baseline in Clinical Laboratory Measure: Potential of Hydrogen (pH)

Clinical laboratory evaluation included: Urinalysis (pH). The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · pH
Change From Baseline in Clinical Laboratory Measure: Potential of Hydrogen (pH)
pHSAGE-547
Change From Baseline at Day 2 (24 hrs)-0.17 ± 1.155
Change From Baseline at Day 3 (48 hrs)0.33 ± 0.289
Change From Baseline at Day 4 (84 hrs)1.00 ± 0.000
PrimaryChange From Baseline in Clinical Laboratory Measure: Specific Gravity

Clinical laboratory evaluation included: Urinalysis (specific gravity) expressed in terms of ratio. The data was collected at time-points on Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs).

Time frame:
Baseline, Days 2 (at 24 hrs), 3 (at 48 hrs) and 4 (at 84 hrs)
Reported as:
Mean · ratio
Change From Baseline in Clinical Laboratory Measure: Specific Gravity
ratioSAGE-547
Change From Baseline at Day 2 (24 hrs)-0.0080 ± 0.00458
Change From Baseline at Day 3 (48 hrs)-0.0017 ± 0.00252
Change From Baseline at Day 4 (84 hrs)-0.0015 ± 0.00495
PrimaryChange From Baseline in Vital Sign: Blood Pressure

Vital sign parameters included supine systolic blood pressure (SBP), supine diastolic blood pressure (DBP), standing systolic blood pressure and standing diastolic blood pressure expressed in terms of millimeters of mercury (mmHg). The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).

Time frame:
Baseline, Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)
Reported as:
Mean · mmHg
Change From Baseline in Vital Sign: Blood Pressure
mmHgSAGE-547
Change From Baseline at Day 1 (12 hrs): Supine SBP-2.8 ± 13.65
Change From Baseline at Day 2 (24 hrs): Supine SBP2.3 ± 11.95
Change From Baseline at Day 2 (36 hrs): Supine SBP-1.0 ± 15.19
Change From Baseline at Day 3 (48 hrs): Supine SBP-5.0 ± 4.40
Change From Baseline at Day 3 (60 hrs): Supine SBP12.3 ± 17.75
Change From Baseline at Day 4 (72 hrs): Supine SBP5.0 ± 23.73
Change From Baseline at Day 4 (84 hrs): Supine SBP8.0 ± 20.69
Change From Baseline at Day 1 (12 hrs): Supine DBP-1.3 ± 12.50
Change From Baseline at Day 2 (24 hrs): Supine DBP3.0 ± 6.83
Change From Baseline at Day 2 (36 hrs): Supine DBP-2.3 ± 5.68
Change From Baseline at Day 3 (48 hrs): Supine DBP-5.0 ± 5.42
Change From Baseline at Day 3 (60 hrs): Supine DBP4.0 ± 6.22
Change From Baseline at Day 4 (72 hrs): Supine DBP0.5 ± 9.75
Change From Baseline at Day 4 (84 hrs): Supine DBP7.5 ± 10.21
Change From Baseline at Day 1(12 hrs):Standing SBP-4.0 ± 7.87
Change From Baseline at Day 2(24 hrs):Standing SBP-1.5 ± 8.23
Change From Baseline at Day 2(36 hrs):Standing SBP-0.8 ± 7.27
Change From Baseline at Day 3(48 hrs):Standing SBP-1.5 ± 7.68
Change From Baseline at Day 3(60 hrs):Standing SBP16.8 ± 2.50
Change From Baseline at Day 4(72 hrs):Standing SBP0.3 ± 11.53
Change From Baseline at Day 4(84 hrs):Standing SBP-0.7 ± 8.74
Change From Baseline at Day 1(12 hrs):Standing DBP1.0 ± 8.52
Change From Baseline at Day 2(24 hrs):Standing DBP6.3 ± 4.11
Change From Baseline at Day 2(36 hrs):Standing DBP1.5 ± 9.11
Change From Baseline at Day 3(48 hrs):Standing DBP7.5 ± 5.92
Change From Baseline at Day 3(60 hrs):Standing DBP13.8 ± 8.81
Change From Baseline at Day 4(72 hrs):Standing DBP13.3 ± 8.14
Change From Baseline at Day 4(84 hrs):Standing DBP10.3 ± 3.06
PrimaryChange From Baseline in Vital Sign: Heart Rate

Vital sign parameter included heart rate expressed in terms of beats per minute (bpm). The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).

Time frame:
Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)
Reported as:
Mean · bpm
Change From Baseline in Vital Sign: Heart Rate
bpmSAGE-547
Change From Baseline at Day 1 (12 hrs)-2.5 ± 15.35
Change From Baseline at Day 2 (24 hrs)5.3 ± 18.84
Change From Baseline at Day 2 (36 hrs)-2.3 ± 11.44
Change From Baseline at Day 3 (48 hrs)-1.5 ± 11.56
Change From Baseline at Day 3 (60 hrs)-3.0 ± 8.41
Change From Baseline at Day 4 (72 hrs)-5.8 ± 7.63
Change From Baseline at Day 4 (84 hrs)-0.8 ± 4.99
PrimaryChange From Baseline in Vital Sign: Body Temperature

Vital sign parameter included temperature expressed in terms of degree Celsius. The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).

Time frame:
Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)
Reported as:
Mean · degree Celsius
Change From Baseline in Vital Sign: Body Temperature
degree CelsiusSAGE-547
Change From Baseline at Day 1 (12 hrs)-0.20 ± 0.32
Change From Baseline at Day 2 (24 hrs)0.15 ± 0.23
Change From Baseline at Day 2 (36 hrs)-0.15 ± 0.33
Change From Baseline at Day 3 (48 hrs)-0.05 ± 0.25
Change From Baseline at Day 3 (60 hrs)0.03 ± 0.31
Change From Baseline at Day 4 (72 hrs)-0.30 ± 0.37
Change From Baseline at Day 4 (84 hrs)-0.45 ± 0.46
PrimaryChange From Baseline in Vital Sign: Respiratory Rate

Vital sign parameter included respiratory rate expressed in terms of breaths per minute. The data was collected at time-points on Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs).

Time frame:
Baseline, Day 1 (12 hrs) Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 72 and 84 hrs)
Reported as:
Mean · breaths/min
Change From Baseline in Vital Sign: Respiratory Rate
breaths/minSAGE-547
Change From Baseline at Day 1 (12 hrs)0.0 ± 1.63
Change From Baseline at Day 2 (24 hrs)0.0 ± 2.31
Change From Baseline at Day 2 (36 hrs)0.0 ± 2.31
Change From Baseline at Day 3 (48 hrs)0.0 ± 4.00
Change From Baseline at Day 3 (60 hrs)0.3 ± 1.53
Change From Baseline at Day 4 (72 hrs)-1.0 ± 1.15
Change From Baseline at Day 4 (84 hrs)-0.5 ± 1.00
PrimaryChange From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, PR Interval, QTc Interval, and QRS Duration

ECGs parameters included QT interval, PR interval, QTc interval, QRS duration expressed in terms of milliseconds (msec).

Time frame:
Baseline, Day 4 (at 84 hrs)
Reported as:
Mean · msec
Change From Baseline in Electrocardiogram (ECG) Parameters: QT Interval, PR Interval, QTc Interval, and QRS Duration
msecSAGE-547
Change from Baseline at Day 4 (84 hrs):QT Interval-28.5 ± 34.31
Change from Baseline at Day 4 (84 hrs):PR Interval-1.0 ± 9.87
Change from Baseline at Day 4(84 hrs):QTc Interval13.3 ± 10.44
Change from Baseline at Day 4(84 hrs):QRS Duration-3.5 ± 7.19
PrimaryChange From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate

ECGs parameter included heart rate expressed in terms of beats per minute (bpm).

Time frame:
Baseline, Day 4 (at 84 hrs)
Reported as:
Mean · bpm
Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate
bpmSAGE-547
Change From Baseline in Electrocardiogram (ECG) Parameter: Heart Rate14.3 ± 9.29
PrimaryNumber of Participants With Physical Examination Findings

Physical examinations included body weight, height, body mass index (BMI) and assessment of body systems (e.g., head, eyes, ears, nose, throat, lungs, abdomen, and extremities) as well as cognitive and mental health examinations (components of the neurological and psychiatric examinations, respectively).

Time frame:
At Day 4
Reported as:
Count of participants · Participants
Number of Participants With Physical Examination Findings
ParticipantsSAGE-547
Number of Participants With Physical Examination Findings4
PrimaryNumber of Participants With Concomitant Medication Usage

Concomitant medications are other prescription medications, over the counter (OTC) drugs or dietary supplements that a study participant takes in addition to the drug under investigation.

Time frame:
Baseline up to Day 11
Reported as:
Count of participants · Participants
Number of Participants With Concomitant Medication Usage
ParticipantsSAGE-547
Number of Participants With Concomitant Medication Usage3
PrimaryNumber of Participants With Suicidal Ideation and Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)

C-SSRS scale consists of a baseline evaluation that assesses the lifetime experience of the participant with suicidal ideation and behavior, and a post-baseline evaluation that focuses on suicidality since the last study visit. The C-SSRS includes 'yes' or 'no' responses for assessment of suicidal ideation and behavior as well as numeric ratings for severity of ideation, (with score range from 1 to 5, higher score indicates more severity). The data was collected at time-points: Pre-infusion (Day 1 prior to dosing), Post-infusion (any time after the start of infusion on Day 1 up to 84 hrs).

Time frame:
Pre-infusion (Day 1 prior to dosing), Post-infusion (any time after the start of infusion on Day 1 up to 84 hrs)
Reported as:
Count of participants · Participants
Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia-Suicide Severity Rating Scale (C-SSRS)
ParticipantsSAGE-547
Pre-Infusion: Suicidal Ideation3
Post-Infusion: Suicidal Ideation0
Pre-Infusion: Suicidal Behavior1
Post-Infusion: Suicidal Behavior0
SecondaryMaximum Plasma Concentration (Cmax) of SAGE-547
Time frame:
Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose
Reported as:
Mean · nanograms per millilter (ng/mL)
Maximum Plasma Concentration (Cmax) of SAGE-547
nanograms per millilter (ng/mL)SAGE-547
Maximum Plasma Concentration (Cmax) of SAGE-54797.2 ± 77.3
SecondaryTime to Maximum Plasma Concentration (Tmax) of SAGE-547

Tmax is defined as the time at which Cmax of SAGE-547 occurred.

Time frame:
Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose
Reported as:
Median · hours
Time to Maximum Plasma Concentration (Tmax) of SAGE-547
hoursSAGE-547
Time to Maximum Plasma Concentration (Tmax) of SAGE-54742 (12 to 48)
SecondaryArea Under the Concentration-Time Curve From Start of the Infusion Until the Time of the Last Sample (AUCall) of SAGE-547

AUCall is defined as the area under the plasma SAGE-547 concentration time curves from the start of the infusion until the time the last sample was taken 72 hours later.

Time frame:
Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose
Reported as:
Mean · nanograms*hour per milliliter (ng*hr/mL)
Area Under the Concentration-Time Curve From Start of the Infusion Until the Time of the Last Sample (AUCall) of SAGE-547
nanograms*hour per milliliter (ng*hr/mL)SAGE-547
Area Under the Concentration-Time Curve From Start of the Infusion Until the Time of the Last Sample (AUCall) of SAGE-5473380 ± 1410
SecondaryArea Under the Concentration-Time Curve From Time Zero to 60 Hours (AUC0-60) of SAGE-547

AUC0-60 is defined as the area under the plasma SAGE-547 concentration time curve during the intravenous infusion.

Time frame:
Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, and 60 hrs post-dose
Reported as:
Mean · ng*hr/mL
Area Under the Concentration-Time Curve From Time Zero to 60 Hours (AUC0-60) of SAGE-547
ng*hr/mLSAGE-547
Area Under the Concentration-Time Curve From Time Zero to 60 Hours (AUC0-60) of SAGE-5473160 ± 1360
SecondaryArea Under the Concentration-Time Curve in 24 Hours (AUC24) of SAGE-547

AUC24 is defined as the area under the plasma SAGE-547 concentration-time curve in a 24-hour period during the maintenance dose.

Time frame:
Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, and 24 hrs post-dose
Reported as:
Mean · ng*hr/mL
Area Under the Concentration-Time Curve in 24 Hours (AUC24) of SAGE-547
ng*hr/mLSAGE-547
Area Under the Concentration-Time Curve in 24 Hours (AUC24) of SAGE-5471590 ± 580
SecondaryAverage Drug Concentration in the Plasma at Steady State During a Dosing Interval (Cavg) of SAGE-547

Cavg is defined as the plasma concentration of SAGE-547 at steady-state (average plasma concentration during the maintenance dose period; nominally 12 to 48 hrs).

Time frame:
From 12 to 48 hrs (36 hr of maintenance dose period)
Reported as:
Mean · ng/mL
Average Drug Concentration in the Plasma at Steady State During a Dosing Interval (Cavg) of SAGE-547
ng/mLSAGE-547
Average Drug Concentration in the Plasma at Steady State During a Dosing Interval (Cavg) of SAGE-54766.1 ± 24.1
SecondaryPlasma Clearance (CL) of SAGE-547

Clearance of a drug was a measure of the rate at which a drug was metabolized or eliminated by normal biological processes.

Time frame:
Predose (0 hrs), and 0.5, 1, 2, 3, 4, 6, 12, 24, 36, 40, 44, 48, 60, and 72 hrs post-dose
Reported as:
Mean · Liters per hour per kilogram (L/hr/kg)
Plasma Clearance (CL) of SAGE-547
Liters per hour per kilogram (L/hr/kg)SAGE-547
Plasma Clearance (CL) of SAGE-5471.08 ± 0.22
SecondaryChange From Baseline in Hamilton Rating Scale for Depression-17 (HAM-D-17) Total Score

The HAM-D-17 was used to rate the severity of depression in participants who were already diagnosed as depressed. The HAM-D-17 is comprised of 17 individual items: Items scored in a range of 0 to 2 include: insomnia (early, middle, late), somatic symptoms (gastrointestinal and general), genital symptoms, loss of weight, and insight. The following items are scored in a range of 0 to 4: agitation, depressed mood, feelings of guilt, suicide, work and activities, retardation, anxiety (psychic and somatic), and hypochondriasis, where 0 indicated none/absent and higher scores indicated greater depression. The Total Score can range from 0 (least depression) to 52 (greater depression), and higher scores indicate a greater degree of depression. A negative change from baseline indicates less depression. A positive change from baseline indicates more depression.

Time frame:
Baseline, Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), Day 3 (at 48 and 60 hrs), and Day 4 (at 84 hrs)
Reported as:
Mean · score on a scale
Change From Baseline in Hamilton Rating Scale for Depression-17 (HAM-D-17) Total Score
score on a scaleSAGE-547
Change From Baseline at Day 1 (12 hrs)-21.8 ± 5.50
Change From Baseline at Day 2 (24 hrs)-23.3 ± 4.19
Change From Baseline at Day 2 (36 hrs)-24.8 ± 3.59
Change From Baseline at Day 3 (48 hrs)-24.3 ± 4.99
Change From Baseline at Day 3 (60 hrs)-24.8 ± 4.19
Change From Baseline at Day 4 (84 hrs)-21.3 ± 6.85
SecondaryClinical Global Impression-Improvement (CGI-I) Score

The CGI-I response was defined as having a score of 1 (very much improved) or 2 (much improved). CGI-I assessment employs a 7-point Likert scale to measure the improvement in the participant's condition. The investigator rated the participant's total improvement whether or not it was due entirely to drug treatment. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse. The CGI-I was only rated at post-treatment assessments. By definition, all CGI-I assessments were evaluated against baseline conditions.

Time frame:
Day 1 (12 hrs), Day 2 (at 24 and 36 hrs), on Day 3 (at 48 and 60 hrs), and Day 4 (at 84 hrs)
Reported as:
Mean · score on a scale
Clinical Global Impression-Improvement (CGI-I) Score
score on a scaleSAGE-547
Day 1 (12 hrs)1.8 ± 0.50
Day 2 (24 hrs)1.3 ± 0.50
Day 2 (36 hrs)1.0 ± 0.00
Day 3 (48 hrs)1.3 ± 0.50
Day 3 (60 hrs)1.3 ± 0.50
Day 4 (84 hrs)1.5 ± 0.58

Adverse events

Collected over AEs: Up to Day 11; SAEs: Up to Day 34. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
SAGE-5470/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Most frequent other events
EventSAGE-547
SedationNervous system disorders2/4
Infusion Site DiscomfortGeneral disorders1/4
Infusion Site ErythemaGeneral disorders1/4
Infusion Site PainGeneral disorders1/4
Blood Thyroid Stimulating Hormone IncreasedInvestigations1/4
DizzinessNervous system disorders1/4
Oropharyngeal PainRespiratory, thoracic and mediastinal disorders1/4
RashSkin and subcutaneous tissue disorders1/4
FlushingVascular disorders1/4

Baseline characteristics

Safety population included all participants who began infusion with SAGE-547 injection.

Age, Continuous
Age, Continuous(years)SAGE-547
Mean32.0 ± 6.88
Sex: Female, Male
Sex: Female, Male(Participants)SAGE-547
Female4
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)SAGE-547
Hispanic or Latino0
Not Hispanic or Latino4
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)SAGE-547
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White3
More than one race0
Unknown or Not Reported0
08

Study locations

1 site
  • Sage Investigational Site
    Chapel Hill, North Carolina 27514, United States
09

References and documents

Individual participant data

Plan to share: No — Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Jun 2015, 4 months.

Results were first posted in Dec 2021, 6 years 5 months after primary completion. A results delay was requested in Apr 2017.

Of 14 phase 2 interventional studies under Depression, Postpartum, half reached primary completion within 17 months of starting (the median); a quarter within 10 and three quarters within 30. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2014
First posted
Nov 7, 2014
StartActual
Jan 7, 2015
Primary completionActual
Jun 5, 2015
CompletionActual
Jun 5, 2015
Results delay requested
Apr 25, 2017
Results first posted
Dec 2, 2021
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02285504
Responsible party
Sponsor
First posted
Nov 7, 2014
Start date
Jan 7, 2015
Primary completion
Jun 5, 2015
Completion
Jun 5, 2015
Results posted
Dec 2, 2021
Last update
Sep 15, 2025

Study contacts

Stephen J Kanes, MD, PhD
study chair · Sage Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Brexanolone

Start the discussion